Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
To evaluate the safety and potential therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in the treatment of patients with severe, sight-threatening, intermediate and posterior noninfectious uveitis, a nonrandomized, open-label, pilot study was performed. Patients with uveitis were treated with a minimum of 20 mg of prednisone, cyclosporine, antimetabolites, or any combination of these agents were eligible. Patients were weaned off their systemic immunosuppressive agents according to a standardized schedule, while ultimately receiving Daclizumab infusions every 4 weeks. Anti-IL-2 receptor antibody therapy, given intravenously with intervals of up to 4 weeks in lieu of standard immunosuppressive therapy, appeared to prevent the expression of severe sight-threatening intraocular inflammatory disease in 8 of 10 patients treated over a 12-month period, with noted improvements in visual acuity. One patient met a primary endpoint with a loss of vision of 10 letters or more from baseline in one eye and another patient discontinued therapy because of evidence of increased ocular inflammation. All patients were able to tolerate the study medications without the need for dose reduction. We report effective long-term use of anti-IL-2 therapy for an autoimmune indication. These initial findings would suggest that anti-IL-2 receptor therapy may be an effective therapeutic approach for uveitis and, by implication, other disorders with a predominant Th1 profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764
Dialysis Dose and Intradialytic Hypotension: Results from the HEMO Study
Mc Causland, F. R., Brunelli, S. M., & Waikar, S. S. (2013) · American Journal of Nephrology · doi:10.1159/000355958 · Cited by 2,690
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,142
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684
Self-citationHogan, M. J., Kimura, S. J., & Thygeson, P. (1959) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)78239-x · Cited by 527
T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat.
Caspi, R. R., Roberge, F. G., McAllister, C. G., el-Saied, M., Kuwabara, T., Gery, I., Hanna, E., & Nussenblatt, R. B. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.3.928 · Cited by 358
Self-citationDepper, J. M., Leonard, W. J., Robb, R. J., Waldmann, T. A., & Greene, W. C. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.2.690 · Cited by 246
Self-citationAutoimmunity : physiology and disease
Coutinho, A., & Kazatchkine, M. D. (1993) · Wiley-Liss eBooks · Cited by 111
Guex‐Crosier, Y., Raber, J. M., Chan, C., Kriete, M. S., Bénichou, J., Pilson, R., Kerwin, J. A., Waldmann, T. A., Hakimi, J., & ROBERGE, F. G. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.1.452 · Cited by 71
Self-citation
Cited by
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Self-citationJabs, D. A., Rosenbaum, J. T., Foster, C. S., Holland, G. N., Jaffe, G. J., Louie, J. S., Nussenblatt, R. B., Stiehm, E. R., Tessler, H., Van Gelder, R. N., et al. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00659-0 · Cited by 995
Self-citationTH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1
Amadi-Obi, A., Yu, C.-R., Liu, X., Mahdi, R. M., Clarke, G. L., Nussenblatt, R. B., Gery, I., Lee, Y. S., & Egwuagu, C. E. (2007) · Nature Medicine · doi:10.1038/nm1585 · Cited by 865
Self-citationInterleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T. A., McFarland, H., Henkart, P. A., & Martin, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601335103 · Cited by 597
Self-citation
Metadata
- Authors
- Nussenblatt, R. B., Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., & Whitcup, S. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-06-22
- Volume
- 96
- Issue
- 13
- Pages
- 7462-7466
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2145153016
- Cited by
- 259
- References
- 11
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.